Press release
Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024
Discover the latest drugs and treatment options in the Stargardt Disease Pipeline. Dive into DelveInsight's comprehensive report today! @ Stargardt Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Stargardt Disease Pipeline Report
* In August 2024:- Belite Bio Inc.- A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease.
* DelveInsight's Stargardt Disease pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
* The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
* Promising Stargardt Disease Therapies such as OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
Stay ahead with the most recent pipeline outlook for Stargardt Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Stargardt Disease Treatment Drugs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Stargardt Disease Emerging Drugs Profile
* Tinlarebant: Belite Bio
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the U.S., Europe, and Japan for the treatment of STGD1. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Stargardt disease.
* KIO-301: Kiora Pharmaceuticals
KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain. Removal of light causes KIO-301 to revert to its original shape, halting signaling. Essentially, KIO-301 acts as a light switch within the eye, restoring light sensitivity in patients with retinal degeneration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of stargardt disease.
* OCU410: Ocugen
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of stargardt disease.
Explore groundbreaking therapies and clinical trials in the Stargardt Disease Pipeline. Access DelveInsight's detailed report now! @ New Stargardt Disease Drugs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Stargardt disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Stargardt Disease Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Stargardt Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Stargardt Disease Market Drivers and Barriers [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Stargardt Disease Pipeline Report
* Coverage- Global
* Stargardt Disease Companies- Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio, and others.
* Stargardt Disease Therapies- OCU410ST, Tinlarebant, ALK-001, ACDN-01, avacincaptad pegol, and others.
* Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Stargardt Disease Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Stargardt Disease Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Stargardt Disease: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Stargardt disease - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tinlarebant: Belite Bio
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* KIO-301: Kiora Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* OCU410: Ocugen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Stargardt disease Key Companies
* Stargardt disease Key Products
* Stargardt disease -Unmet Needs
* Stargardt disease -Market Drivers and Barriers
* Stargardt disease -Future Perspectives and Conclusion
* Stargardt disease Analyst Views
* Stargardt disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stargardt-disease-clinical-trials-pipeline-insights-treatment-drugs-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Stargardt Disease Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024 here
News-ID: 3661656 • Views: …
More Releases from ABNewswire
Marketing Strategist Katina Ndlovu Demonstrates How Google Local Services Ads Ca …
This case study examines how a service-based business generated 280 high-intent leads in two months using Google Local Services Ads by focusing on phone-driven enquiries, trust signals, and operational readiness rather than traffic volume. The campaign achieved consistent top-of-search visibility, capturing decision-ready customers and producing stable inbound demand. It highlights why aligning marketing systems with real buyer behaviour is essential for sustainable local growth.
Johannesburg, South Africa - Marketing strategy consultant…
How to Build a Red Light + Skincare Regimen for Visible Results All Year
Mito Red Light is pioneering a new category of skincare known as Light-Activated Skincare, combining red and near-infrared light therapy with topical formulations designed to respond to light exposure. The company's latest educational release outlines how to build a year-round red light skincare regimen using its MitoAURA Trademark Activate + Amplify Serum, while announcing an upcoming split-face study to evaluate the added benefits of light-activated skincare compared to light therapy…
Why Self-Assessment Tax Software Is Now the First Choice for UK Taxpayers
As HMRC continues to encourage online interaction, self-assessment tax software is now a standard tool rather than an optional extra. Software-based filing supports accuracy, improves compliance, and saves time for both taxpayers and the tax authority. Pie's platform reflects this shift, focusing on simplicity, trust, and accessibility, while reinforcing its core belief: "It's your money. Claim it."
LONDON, United Kingdom - Self-assessment tax software has become the preferred way for millions…
Independent Leadership Survey Names 2025's Lowest-Rated CEO
SAN FRANCISCO, CA - February 9, 2026 - In a surprising and controversial turn of events in the fictional business world, the CEO of the Google AdWords division has been ranked as the lowest-performing chief executive officer of 2025in the newly released Global Executive Satisfaction Index (GESI) - a yearly survey of business leaders, marketing professionals, and industry observers designed to assess executive leadership performance across major technology companies. (This…
More Releases for Stargardt
Stargardt Disease Market Dynamics Indicate Upward Trajectory Through 2034, Repor …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
Stargardt Disease Market was valued at USD 120-150 million in 2024
Market Overview
The Stargardt Disease market is expanding steadily as advancements in retinal imaging, genetic testing, and gene-therapy research accelerate therapeutic development. Stargardt Disease, the most common form of inherited juvenile macular degeneration, is caused primarily by mutations in the ABCA4 gene and leads to progressive central vision loss.
The global market for Stargardt Disease diagnosis, management, and emerging therapeutics was valued at USD 120-150 million in 2024. With increasing clinical-trial activity…
Stargardt Disease Market to Witness Promising Upswing by 2034, DelveInsight Fore …
The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stargardt Disease pipeline products will significantly revolutionize the Stargardt Disease market dynamics.
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United…
Stargardt Disease Pipeline, Clinical Trials, Emerging Therapies, and FDA Approva …
DelveInsight's, "Stargardt Disease Pipeline Insight 2023" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Stargardt Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Global Juvenile Degeneration (Stargardt Disease) Market Forecast to 2025
Juvenile Degeneration (Stargardt Disease) Market report describes the thorough and collective examination of the Juvenile Degeneration (Stargardt Disease) industry during the past, present and conjecture periods. All the business verticals like driving market situation, regional Juvenile Degeneration (Stargardt Disease) nearness, and improvement openings are clarified. Top players of the Juvenile Degeneration (Stargardt Disease) industry, their business strategies, and growth opportunities are covered in this report. A report is incomplete without…
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review and Research …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2017” to its report offerings. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action…
